SNY - Sanofi
NASDAQ
->
Healthcare
->
Drug Manufacturers—General
Paris,
France
Type: Equity
SNY price evolution
SNY
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6795 | $8710 | ||
| Short term investments | ||||
| Net receivables | $8805 | $391 | ||
| Inventory | $10609 | $21554 | ||
| Total current assets | $30081 | $30670 | ||
| Long term investments | $2640 | $2666 | ||
| Property, plant & equipment | $11880 | $11814 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $129755 | $126314 | ||
| Current liabilities | ||||
| Accounts payable | $7433 | $20882 | ||
| Deferred revenue | ||||
| Short long term debt | $9515 | $2320 | ||
| Total current liabilities | $30027 | $24020 | ||
| Long term debt | $14236 | $16102 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $56758 | $51961 | ||
| Shareholders' equity | ||||
| Retained earnings | $65093 | $67499 | ||
| Other shareholder equity | $71518 | $313 | ||
| Total shareholder equity | $72997 | $74353 | ||
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $8710 | $1385 | $10098 | $13915 |
| Short term investments | $1054 | $900 | ||
| Net receivables | $391 | $374 | $612 | $9953 |
| Inventory | $9666 | $20916 | $19854 | $8352 |
| Total current assets | $30670 | $34026 | $30564 | $33703 |
| Long term investments | $2666 | $2765 | $7975 | $2129 |
| Property, plant & equipment | $11814 | $11684 | $11976 | $10563 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $92327.54 | |||
| Total investments | ||||
| Total assets | $126314 | $124585 | $120242 | $114529 |
| Current liabilities | ||||
| Accounts payable | $20882 | $18834 | $17397 | $5295 |
| Deferred revenue | ||||
| Short long term debt | $2320 | $4451 | $3452 | $2999 |
| Total current liabilities | $24020 | $23964 | $21295 | $19248 |
| Long term debt | $16102 | $16761 | $18962 | $20725 |
| Total noncurrent liabilities | $36706.66 | |||
| Total debt | ||||
| Total liabilities | $51961 | $51441 | $51561 | $51528 |
| Shareholders' equity | ||||
| Retained earnings | $67499 | $68590.55 | ||
| Other shareholder equity | $313 | $73144 | $68681 | $1142 |
| Total shareholder equity | $74353 | $75152 | $68681 | $63001 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $14157 | $11380 | $11118 | $12201 |
| Cost of revenue | $3391 | $3439 | $4048 | |
| Gross Profit | $10072 | $7989 | $7679 | $8153 |
| Operating activities | ||||
| Research & development | $1704 | $1719 | $1872 | |
| Selling, general & administrative | $2695 | $2605 | $2931 | |
| Total operating expenses | $5983 | $9752 | $9086 | $10234 |
| Operating income | $1628 | $2032 | $1967 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $737 | $299 | $164 | $309 |
| Interest expense | -$140 | -$54 | -$253 | -$625 |
| Net income | ||||
| Net income | $2815 | $1113 | $1133 | -$555 |
| Income (for common shares) | $1113 | $1133 | -$555 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $46444 | $45389 | $39175 | $37369 |
| Cost of revenue | $14236 | $13692 | $12255 | $12157 |
| Gross Profit | $32208 | $31697 | $26920 | $25212 |
| Operating activities | ||||
| Research & development | $6728 | $6706 | $5692 | $5527 |
| Selling, general & administrative | $10692 | $10539 | $9555 | $9290 |
| Total operating expenses | $36052 | $34351 | $31049 | $23228 |
| Operating income | $10392 | $11038 | $8126 | $14141 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $1602 | $2006 | $1558 | $1813 |
| Interest expense | -$1313 | -$394 | -$7382 | |
| Net income | ||||
| Net income | $5400 | $8371 | $6223 | $12314 |
| Income (for common shares) | $5400 | $8371 | $6223 | $12314 |
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$3413 | -$6200 | -$3073 | -$2075 |
| Financing activities | ||||
| Dividends paid | -$4704 | -$4454 | -$4454 | -$4168 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $89 | -$8052 | -$5214 | -$5821 |
| Effect of exchange rate | -$14 | -$32 | -$19 | $8 |
| Change in cash and equivalents | -$1915 | -$4026 | -$4743 | $2638 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $5400 | $6223 | $12314 | |
| Operating activities | ||||
| Depreciation | $1385 | $3351 | $3684 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $10258 | $10522 | $7449 | |
| Investing activities | ||||
| Capital expenditures | -$1719 | -$2043 | -$2114 | |
| Investments | ||||
| Total cash flows from investing | -$6200 | -$2075 | -$7298 | $3588 |
| Financing activities | ||||
| Dividends paid | -$4454 | -$4168 | -$4008 | -$3937 |
| Sale and purchase of stock | -$398 | -$196 | -$619 | |
| Net borrowings | -$3136 | -$2804 | -$1885 | |
| Total cash flows from financing | -$8052 | -$5821 | -$7056 | -$6485 |
| Effect of exchange rate | -$2 | $8 | $15 | -$64 |
| Change in cash and equivalents | -$4026 | $2638 | -$3817 | $4488 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $48.86B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $4.51B |
| Revenue Q/Q | 11.49% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.70 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |